12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/Carbidopa

NCT ID: NCT00456586

Last Updated: 2024-04-25

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 180 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2002-04-30
• Study Completion Date: 2003-06-30

Brief Summary

12-week, double-blind, placebo-controlled, multicenter, randomized study designed to evaluate the safety and efficacy of 40 mg/day istradefylline compared with placebo in subjects with OFF phenomena advanced PD who were treated with levodopa/carbidopa.

Detailed Description

A 12-week, double-blind, placebo-controlled, multicenter, randomized study designed to evaluate the safety and efficacy of 40 mg/day istradefylline compared with placebo in subjects with OFF phenomena advanced PD who were treated with levodopa/carbidopa.

Conditions

Parkinson's Disease

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Interventions

KW-6002 (istradefylline)

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. United Kingdom Parkinson's Disease Society brain bank diagnostic criteria (step 1 and 2).

2. Modified Hoehn and Yahr Scale II-IV in the OFF state.

3. Treated with levodopa/carbidopa for 1 year with a stable regimen for 4 weeks prior to randomization.

4. Taking at least 4 doses of levodopa (3 doses if at least 2 doses containing slow release formulation) per day with predictable end of dose wearing off.

5. Successfully completed Parkinson's disease patient diary training with at least 120 minutes of OFF time per day.

6. Stable regimen of other antiparkinson's disease medications for at least 4 weeks prior to randomization.

7. At least 30 years of age and able to give written informed consent.

Exclusion Criteria

1. Treatment with liquid levodopa/carbodopa within 4 weeks of randomization.

2. Treatment with MAO inhibitors except selegiline.

3. Treatment with centrally acting dopamine antagonists within 3 months (6 months for depot preparations), e.g., antipsychotic neuroleptics, metoclopramide, buspirone, amoxapine.

4. Neurosurgical surgery for Parkinson's disease.

5. Atypical parkinsonism or secondary parkinsonism variants.

6. Diagnosis of cancer or evidence of continued cancer within 5 years of enrollment or clinically significant illness of any organ system (e.g., ALT or AST > 1.5 times the upper limit of normal).

7. Mini-Mental Status Examination score of 25 or less.

8. History of drug or alcohol abuse or dependence within 2 years.

9. History of psychotic illness or seizures.

10. Current clinically relevant depression disorder.

11. History of neuroleptic malignant syndrome.

12. Pregnant or lactating females. Women of child-bearing potential must use reliable method of contraception.

• Minimum Eligible Age: 30 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Kyowa Kirin, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Neil Sussman, MD

Role: STUDY_DIRECTOR

Kyowa Kirin, Inc.

Locations

Contact Kyowa Pharmacuetical Inc.

Princeton, New Jersey, United States

Countries

United States

Other Identifiers

6002-US-005

Identifier Type: -

Identifier Source: org_study_id